Brief: Acurx Announces New Data From Phase 2A Clinical Trial Of C. Difficile Treatment
08/11/2021 13:27
Nov 8 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES NEW MICROBIOME DATA FROM ITS PHASE 2A
CLINICAL
TRIAL OF IBEZAPOLSTAT FOR CDI AT THE 9TH INTERNATIONAL C. DIFF.
CONFERENCE
* ACURX PHARMACEUTICALS INC - RESULTS SUPPORT EXPECTATION
THAT
MICROBIOME EFFECTS MAY BE PREDICTIVE OF BENEFICIAL OUTCOMES, LOW
RATES OF RECURRENCE
* ACURX PHARMACEUTICALS INC - PHASE 2B TRIAL COMPARING
IBEZAPOLSTAT TO VANCOMYCIN IN CDI PATIENTS TO BEGIN THIS MONTH
Source text for Eikon: ID:nPn3wqm8Xa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program